PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2013 May 4

PMID 23640975

Citations 44

Authors

Amanda Herzog

Yansong Bian

Robert Vander Broek

Bradford Hall

Jamie Coupar

Hui Cheng

Anastasia L Sowers

John D Cook

James B Mitchell

Zhong Chen

Ashok B Kulkarni

Carter Van Waes

Affiliations

Soon will be listed here.

Abstract

Purpose: Phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway activation is often associated with altered expression or mutations of PIK3CA, TP53/p73, PTEN, and TGF-β receptors (TGFBR) in head and neck squamous cell carcinomas (HNSCC). However, little is known about how these alterations affect response to PI3K/mTOR-targeted agents.

Experimental Design: In this preclinical study, PI3K/Akt/mTOR signaling was characterized in nine HNSCC (UM-SCC) cell lines and human oral keratinocytes. We investigated the molecular and anticancer effects of dual PI3K/mTOR inhibitor PF-04691502(PF-502) in UM-SCC expressing PIK3CA with decreased wild-type TP53, mutant TP53-/+ mutantTGFBR2, and in HNSCC of a conditional Pten/Tgfbr1 double knockout mouse model displaying PI3K/Akt/mTOR activation.

Results: UM-SCC showed increased PIK3CA expression and Akt/mTOR activation, and PF-502 inhibited PI3K/mTORC1/2 targets. In human HNSCC expressing PIK3CA and decreased wtTP53 and p73, PF-502 reciprocally enhanced TP53/p73 expression and growth inhibition, which was partially reversible by p53 inhibitor pifithrin-α. Most UM-SCC with wtTP53 exhibited a lower IC50 than those with mtTP53 status. PF-502 blocked growth in G0-G1 and increased apoptotic sub-G0 DNA. PF-502 suppressed tumorigenesis and showed combinatorial activity with radiation in a wild-type TP53 UM-SCC xenograft model. PF-502 also significantly delayed HNSCC tumorigenesis and prolonged survival of Pten/Tgfbr1-deficient mice. Significant inhibition of p-Akt, p-4EBP1, p-S6, and Ki67, as well as increased p53 and TUNEL were observed in tumor specimens.

Conclusions: PI3K-mTOR inhibition can enhance TP53/p73 expression and significantly inhibit tumor growth alone or when combined with radiation in HNSCC with wild-type TP53. PIK3CA, TP53/p73, PTEN, and TGF-β alterations are potential modifiers of response and merit investigation in future clinical trials with PI3K-mTOR inhibitors.

Citing Articles

In vivo antitumor activity of PHT-427 inhibitor-loaded polymeric nanoparticles in head and neck squamous cell carcinoma.

Yanes-Diaz J, Palao-Suay R, Camacho-Castaneda F, Riestra-Ayora J, Aguilar M, Sanz-Fernandez R Drug Deliv. 2025; 32(1):2449376.

PMID: 39789884 PMC: 11727052. DOI: 10.1080/10717544.2024.2449376.

The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights.

Asiri A, Al Qarni A, Bakillah A Diagnostics (Basel). 2024; 14(19).

PMID: 39410536 PMC: 11475808. DOI: 10.3390/diagnostics14192132.

Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells.

Shang X, Na X, Wang L, Yang Z, Ren P Evid Based Complement Alternat Med. 2022; 2022:8110796.

PMID: 35783514 PMC: 9249467. DOI: 10.1155/2022/8110796.

The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses.

Cui D, Qu R, Liu D, Xiong X, Liang T, Zhao Y Front Cell Dev Biol. 2021; 9:775507.

PMID: 34869377 PMC: 8638743. DOI: 10.3389/fcell.2021.775507.

Hypomethylation and downregulation of miR-23b-3p are associated with upregulated PLAU: a diagnostic and prognostic biomarker in head and neck squamous cell carcinoma.

Huo Z, Li X, Zhou J, Fan Y, Wang Z, Zhang Z Cancer Cell Int. 2021; 21(1):564.

PMID: 34702271 PMC: 8549381. DOI: 10.1186/s12935-021-02251-w.

References

Yuan J, Mehta P, Yin M, Sun S, Zou A, Chen J . PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011; 10(11):2189-99. DOI: 10.1158/1535-7163.MCT-11-0185. View

Dong G, Chen Z, Li Z, Yeh N, Bancroft C, Van Waes C . Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001; 61(15):5911-8. View

Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P . Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 2009; 69(14):5918-26. PMC: 2758611. DOI: 10.1158/0008-5472.CAN-08-4623. View

Stransky N, Egloff A, Tward A, Kostic A, Cibulskis K, Sivachenko A . The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-60. PMC: 3415217. DOI: 10.1126/science.1208130. View

Molinolo A, Hewitt S, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A . Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res. 2007; 13(17):4964-73. DOI: 10.1158/1078-0432.CCR-07-1041. View

Ekshyyan O, Mills G, Lian T, Amirghahari N, Rong X, Lowery-Nordberg M . Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck. 2010; 32(12):1619-28. DOI: 10.1002/hed.21374. View

Poeta M, Manola J, Goldwasser M, Forastiere A, Benoit N, Califano J . TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007; 357(25):2552-61. PMC: 2263014. DOI: 10.1056/NEJMoa073770. View

Ehsanian R, Brown M, Lu H, Yang X, Pattatheyil A, Yan B . YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene. 2010; 29(46):6160-71. PMC: 2991596. DOI: 10.1038/onc.2010.339. View

Nathan C, Franklin S, Abreo F, Nassar R, De Benedetti A, Glass J . Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol. 1999; 17(9):2909-14. DOI: 10.1200/JCO.1999.17.9.2909. View

10.

Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T . Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol. 2002; 198(3):335-42. DOI: 10.1002/path.1207. View

11.

Bancroft C, Chen Z, Yeh J, Sunwoo J, Yeh N, Jackson S . Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer. 2002; 99(4):538-48. DOI: 10.1002/ijc.10398. View

12.

Komarov P, Komarova E, Kondratov R, Coon J, Chernov M, Gudkov A . A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. DOI: 10.1126/science.285.5434.1733. View

13.

Cohen J, Chen Z, Lu S, Yang X, Arun P, Ehsanian R . Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Res. 2009; 69(8):3415-24. PMC: 2696277. DOI: 10.1158/0008-5472.CAN-08-3704. View

14.

Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K . PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci. 2006; 97(12):1351-8. PMC: 11160012. DOI: 10.1111/j.1349-7006.2006.00343.x. View

15.

Markman B, Dienstmann R, Tabernero J . Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2011; 1(7):530-543. PMC: 3248125. DOI: 10.18632/oncotarget.188. View

16.

Min B, Baek J, Shin K, Gujuluva C, Cherrick H, Park N . Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. Eur J Cancer B Oral Oncol. 1994; 30B(5):338-45. DOI: 10.1016/0964-1955(94)90036-1. View

17.

Freudlsperger C, Burnett J, Friedman J, Kannabiran V, Chen Z, Van Waes C . EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets. 2010; 15(1):63-74. PMC: 3399735. DOI: 10.1517/14728222.2011.541440. View

18.

Sun Z, Zhang L, Hall B, Bian Y, Gutkind J, Kulkarni A . Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res. 2012; 18(19):5304-13. PMC: 3463723. DOI: 10.1158/1078-0432.CCR-12-1371. View

19.

Emerling B, Akcakanat A . Targeting PI3K/mTOR signaling in cancer. Cancer Res. 2011; 71(24):7351-9. DOI: 10.1158/0008-5472.CAN-11-1699. View

20.

Czerninski R, Amornphimoltham P, Patel V, Molinolo A, Gutkind J . Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila). 2009; 2(1):27-36. DOI: 10.1158/1940-6207.CAPR-08-0147. View